A 
12.79
+0.47%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ADMA Biologics
From its filings with the US Securities and Exchange Commission
ADMA Biologics is based in Ramsey, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ADMA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $510.2m and net income of $146.9m. At that date it held total assets of $624.2m and shareholders' equity of $477.3m.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Oct 2013
- Employees
- 647
- Website
- admabiologics.com ↗
- Head office
- C/O ADMA BIOLOGICS, INC., RAMSEY, NJ, 07446
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Steven ElmsIndependent Chairman of the Board$351,176
- Mr. Adam GrossmanPresident, Chief Executive Officer, Co-Founder, Director, since 2007$7.9m
- Dr. Jerrold GrossmanVice Chairman of the Board, Co-Founder$344,399
- Mr. Terry KohlerChief Financial Officer, Treasurer
- Ms. Kaitlin KestenbergChief Operating Officer, Senior Vice President - Compliance$3.3m
- Ms. Alison FingerIndependent Director$305,977
- Mr. Lawrence GuiheenIndependent Director$334,774
- Dr. Young KwonIndependent Director$333,240
- Mr. Eduardo SalasIndependent Director$214,537
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 33
- Environment
- 34
- Social
- 46
- Governance
- 18
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ADMA Biologics Inc possesses a robust intellectual property portfolio, which provides a significant competitive advantage in the biologics industry. This comprehensive IP portfolio protects their innovative products and technologies, making it difficult for competitors to replicate or infringe upon their advancements.
- ADMA Biologics Inc has state-of-the-art manufacturing facilities and a well-established production process. Their advanced manufacturing capabilities enable them to efficiently produce high-quality biologics, streamlining the supply chain and ensuring consistent product availability to meet market demands.
Weaknesses
- ADMA Biologics Inc heavily relies on a single manufacturing facility for their production, which poses a potential vulnerability to their supply chain. Any disruption or operational issues at the facility could negatively impact their ability to meet market demand and fulfill orders in a timely manner.
- Currently, ADMA Biologics Inc has a relatively limited product portfolio, focusing primarily on immune globulin products. This narrower range of offerings may limit their revenue potential and leave them more vulnerable to market fluctuations or competition in the biologics industry.
Opportunities
- ADMA Biologics Inc can capitalize on the growing global biologics market by expanding their product offerings and entering new market segments. By diversifying their portfolio, they can target a broader customer base and enhance their revenue potential while taking advantage of increasing demand for biologic therapies worldwide.
- Investing in research and development to develop new products and innovative therapies can open up new revenue streams for ADMA Biologics Inc. By focusing on expanding their pipeline, they can stay ahead of competitors and address unmet medical needs, positioning themselves as a leading player in the biologics market.
Threats
- The biologics industry is highly competitive with numerous established players and new entrants. ADMA Biologics Inc faces the risk of increased competition, pricing pressures, and potential loss of market share if they fail to differentiate their products effectively or keep up with technological advancements and industry trends.
- As a biologics company, ADMA Biologics Inc is subject to rigorous regulatory requirements and quality control standards. Any failure to comply with these regulations or maintaining proper documentation can result in regulatory penalties, product recalls, damage to reputation, and potential legal action, posing a significant threat to their operations and financial stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.